Role of insulin-like growth factor-Ⅰ in prognostic evaluation and treatment of liver cirrhosis
- VernacularTitle:胰岛素样生长因子-Ⅰ（IGF-Ⅰ）在肝硬化预后评估和治疗中的作用
- Author:
Yanping WANG
1
;
Ya ZHENG
2
;
Huifang ZHANG
1
;
Huimin WANG
1
;
Xiaotong MA
1
;
Zhaofeng CHEN
2
Author Information
- Publication Type:Review
- Keywords: Liver Cirrhosis; Hepatic Fibrosis; Insulin-Like Growth Factor Ⅰ; Prognosis
- From: Journal of Clinical Hepatology 2025;41(6):1188-1193
- CountryChina
- Language:Chinese
- Abstract: As a key member of the insulin-like growth factor family， insulin-like growth factor-Ⅰ （IGF-Ⅰ） is mainly synthesized in the liver and is widely distributed in the human body， and it is involved in the physiological processes such as cell proliferation， differentiation， metabolism， and apoptosis. Studies have shown that the level of IGF-Ⅰ is negatively correlated with the severity of liver cirrhosis， and IGF-Ⅰ mainly affects the progression of liver cirrhosis by inhibiting liver fibrosis， promoting DNA damage repair， and regulating lipid metabolism. Monitoring of IGF-Ⅰ level is expected to provide an evaluation indicator for improving the prognosis of patients with liver cirrhosis， and stimulating the action pathway of IGF-Ⅰ or regulating its expression level may become a new method for the treatment of liver cirrhosis. This article reviews the research advances in IGF-Ⅰ in liver cirrhosis， in order to provide new ideas for the diagnosis and treatment of liver cirrhosis.
